Trial record 1 of 1 for:
NCT03358875
Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03358875 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 2, 2017
Last Update Posted : August 12, 2020
|
Sponsor:
BeiGene
Information provided by (Responsible Party):
BeiGene
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2020 |
| Estimated Study Completion Date : | June 2021 |